What one share of TG Therapeutics holds
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S.
TG Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.01 |
|---|---|
| Profit | $2.77 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.11 |
| Cash and investments | $3.15 |
| Debt | $4.87 |
| Book value | $3.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | — | −$0.44 | $0.00 | −$0.04 | — | — |
| 2012 | — | −$1.38 | $0.00 | −$0.40 | — | $0.60 |
| 2013 | — | −$0.81 | $0.00 | −$0.42 | — | $1.17 |
| 2014 | — | −$1.64 | $0.00 | −$1.03 | — | $1.78 |
| 2015 | — | −$1.38 | $0.00 | −$0.98 | — | $1.88 |
| 2016 | $0.00 | −$1.60 | $0.01 | −$1.26 | — | $0.63 |
| 2017 | $0.00 | −$1.91 | $0.00 | −$1.51 | — | $0.92 |
| 2018 | $0.00 | −$2.30 | $0.00 | −$1.71 | — | $0.29 |
| 2019 | $0.00 | −$1.96 | $0.00 | −$1.50 | — | $0.35 |
| 2020 | $0.00 | −$2.42 | $0.00 | −$1.86 | — | $3.69 |
| 2021 | $0.05 | −$2.63 | $0.00 | −$2.24 | — | $1.66 |
| 2022 | $0.02 | −$1.65 | $0.00 | −$1.30 | — | $0.40 |
| 2023 | $1.57 | $0.09 | $0.00 | −$0.21 | — | $1.06 |
| 2024 | $2.05 | $0.15 | $0.00 | −$0.25 | — | $1.43 |
| 2025 | $3.82 | $2.77 | $0.00 | −$0.15 | — | $4.17 |
Common questions about TG Therapeutics
How much does one share of TG Therapeutics earn?
Over the last 12 months, each share of TG Therapeutics earned $2.77 of profit on $5.01 of sales, keeping about 55¢ of every $1 (profit margin).
Does TG Therapeutics pay a dividend?
TG Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is TG Therapeutics’s book value per share?
TG Therapeutics’s book value is $3.95 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of TG Therapeutics have?
Each share of TG Therapeutics has $3.15 of cash and investments and $4.87 of debt, as of June 30, 2026.
What is TG Therapeutics’s free cash flow per share?
$0.11 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has TG Therapeutics bought back shares?
TG Therapeutics’s share count rose about 8280% from 2011 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.